Founded in 1979 and headquartered in Natick, Massachusetts, Lanco is a leading global medical technology company.

In 1997, Lanke entered Huaxia and set up branches and R&D centers in Imperial Capital, Modu and Yangcheng, and the company's headquarters in China is located in Modu.

Lanco's core business areas in China are cardiac intervention, cardiac rhythm management and electrophysiology, structural heart disease, endoscopic intervention, respiratory, peripheral and oncology intervention.

As the world's leading provider of innovative medical solutions, Lanco is committed to long-term investment in innovative R&D.

Orchid has more than 13,000 products and has obtained more than 16,000 granted patents worldwide. In 2013, Ranko's R&D investment reached 861 million US dollars, making it one of the largest medical device companies in the world.

In the process of the rise of cardiovascular interventional surgery in China, Boke Company has obtained huge excess profits and made a lot of money.

And their ambitions don't stop there, whether it is Johnson & Johnson or Medtronic, in terms of business promotion and technology, they are one step ahead of Ranko.

Therefore, Lanke has recently invested a large amount of money to produce consumables for the interventional minimally invasive treatment of mitral regurgitation, which has entered the phase IV clinical stage.

If this business is promoted, Lanco is confident that it will become the leader of cardiac interventional consumables in the United States and even the world.

......

......

In Natick, Massachusetts, in the office of the CEO of Ranko's corporate headquarters, Jack Jones actually signed the paper.

The company's recent research has gotten into trouble, which has upset Jack Jones.

There is a research on high-value consumables for mitral valve clipping under interventional surgery, which is a huge profit growth point for Lanke and the hope of the company.

From 02 years to 13 years of FDA approval, after a lot of hard work, a huge amount of money has been invested.

One week after approval, Professor Saibal Kar, Associate Director of the Cardiovascular Intervention Center at Cedar-Sinai Medical Center, performed the nation's first mitral valve clip for the treatment of life-threatening heart valve disease.

All of this seems to be so perfect, and the continuous progress of technology is the best way to obtain excess profits, which no one knows.

However, technological progress is so difficult, and Lanke can barely support it by virtue of the excess income of the world's top three circular intervention high-value consumables.

Originally, I thought that after 13 years of FDA approval, mitral valve clipping surgery could be successfully promoted around the world, but in the end, the key to the operation was stuck in technology.

The consumables developed by Ranco are mainly used in patients with mitral regurgitation located in the A2P2 region, and the two areas are required to be free of significant calcification or midvalvular fissure.

The latter is not difficult, but requires A2P2 regurgitation, which limits the vast majority of surgeries.

Dr. Saibal Kar, an interventional cardiologist at Cedars-Sinai Medical Center in the United States, who completed the first clinical trial of MitraClip in the United States, worked closely with Ranko.

In 2017, he performed 133 MitraClips in one year, ranking first in the world for the number of surgeries.

It is the first in this world, which gives Ranko a great headache.

The most minimally invasive surgery for mitral regurgitation in the world is only 133!!

Ranko couldn't stand the existence of such a thing.

The technical department wants to improve the technology so that all patients with mitral regurgitation are suitable for surgery. However, several years later, the indication for surgery is still limited to mitral regurgitation in the A2P2 region.

As far as the current situation is concerned, there is no way to recover the huge research costs, let alone excess profits.

This is a headache that every pharmaceutical company and consumables company has to face.

It is often heard that a multinational pharmaceutical company is slumping because of the failure of a promising and heavily invested project.

And although Ranko is not yet out of business, the situation they face is still not optimistic.

In this regard, the company has made many adjustments, and the technical department seems to be working hard to improve, and is looking for world-renowned circulatory interventional surgeons to jointly study.

however

The results were disappointing.

"Knock knock~"

There was a knock on the door.

"Mr. Jones, there's a new email. The door opened, and Jack Jones' assistant bowed slightly and said politely.

"Who's it?" Jack Jones didn't look up, he was reviewing the earnings for the new quarter.

"It's an email from Dr. Wu from Massachusetts General Hospital......"

No matter what he said, he refused. Seb Carr said coldly.

The assistant hesitated, he didn't know why the world's top doctors invited by the company several times in the past sent emails, but Mr. Jack Jones didn't think about it and refused directly.

After a moment's hesitation, the assistant bowed and left.

As soon as the door was about to close, he couldn't help but say, "Mr. Jones......"

"What?" Jack Jones looked up and lifted his glasses, his eyes already showing displeasure.

"You really don't look at your email. ”

"No, I'm busy. Jack Jones didn't say anything else and continued to look down at the earnings report.

"Mr. Carr...... Wu said he could do a full mitral valve clip. The assistant couldn't help but say.

"Reject him......" As soon as he said half a sentence, Seb Carr suddenly raised his head in surprise and looked at his assistant, "What did you just say?"

Wu said in the email that he had found a way to do a full-fledged mitral valve clip. Jack Jones' assistant said.

"......" Jack Jones froze.

The so-called full surgery is a type of surgery that can be applied to all patients with mitral regurgitation, unlike the dilemma faced by the company now, which can only treat patients with mitral regurgitation in the A2P2 area.

All the arts!

This is what Ranko has been pursuing!

Jack Jones's eyes glittered with gold, as if it were the age of the Great Gold Rush, and he alone found a river full of gold sand.

"Print out the mail and give it to me right away. "Jack Jones seems to have forgotten what he said before.

"Yes, Mr. Jones. His assistant bowed and left.

A few minutes later, Jack Jones was holding the mail in his hand, looking at it word by word.

The young man said that he had passed animal experiments and could complete the operation of all-surgical mitral regurgitation. As long as Ranko agrees, they can cooperate.

Of course, Wu directly explained what he needed in the email.

Interventional consumables for congenital heart disease, which is not difficult for Poco. Although the selling price is high, the cost price is low.

What was most difficult for Jack Jones to accept was that Wu actually said that he would not come to the city of Natick and asked Poco to establish the research institute in an unknown place.

To agree or not to disagree, that's the question.

Such a big thing must go through the board of directors, and Jack Jones finally made such a decision.